Basic Sinequan Information

• INN (International Nonproprietary Name): Doxepin.
• Brand Names Available In United States: Sinequan (discontinued in the USA; generics available) and Silenor (3 mg and 6 mg tablets for insomnia).
• ATC Code: N06AA12 (Non-selective monoamine reuptake inhibitors; tricyclic antidepressants).
• Forms & Dosages: Capsules 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; oral solution 10 mg/mL; Silenor tablets 3 mg and 6 mg for insomnia.
• Manufacturers In United States: Generic doxepin capsules are supplied by manufacturers including Mylan and Teva; Silenor tablets are marketed under their insomnia indication.
• Registration Status In United States: FDA — Sinequan brand discontinued, generics of doxepin approved; Silenor remains approved for insomnia.
• OTC / Rx Classification: Prescription only (Rx) in the United States and other major markets.

Key Findings From Recent Trials

Major 2022–2026 Studies

Clinicians and patients ask whether low-dose doxepin is now a go-to for insomnia in older adults.

Several randomized controlled trials and real-world analyses published between 2022 and 2026 focused on low-dose doxepin for sleep maintenance and comparative effectiveness of doxepin for depression versus modern agents.

The insomnia work concentrated on Silenor 3–6 mg nightly and enrolled many elderly or older-adult cohorts with sleep-maintenance complaints.

Comparative effectiveness studies evaluated doxepin against SSRIs and SNRIs in tolerability and first-line depression outcomes.

Main Outcomes

Low-dose Silenor (3–6 mg) showed consistent, clinically meaningful improvements in sleep maintenance measures such as reduced awakenings and longer total sleep time in multiple trials.

Insomnia benefits were achieved with minimal next-day cognitive impairment at the 3–6 mg dose ranges when compared with older sedative-hypnotics in these studies.

For depression, randomized and observational data confirmed that SSRIs and SNRIs generally outperform doxepin on tolerability, leading to declining use of doxepin as a first-line antidepressant.

Where doxepin remains used in depression, it is more often reserved for treatment-resistant presentations or when its sedating or antihistaminic effects are clinically desirable.

Safety Observations

Across datasets the dominant risks at antidepressant doses (for example 75–150 mg/day and above) included anticholinergic effects and sedation.

Case series and pharmacovigilance reports through 2024–25 emphasized overdose-related cardiac arrhythmia risk at higher doses and in mixed-overdose settings.

Trials in elderly insomnia cohorts reported no significant increase in anticholinergic burden when dosed at 3–6 mg at night, but vigilance for urinary retention and daytime sedation remains important.

Clinical Mechanism Of Action

Layman’s Explanation

People want a simple reason why small and large doses act so differently.

At low doses doxepin works mainly as a very strong antihistamine blocking H1 receptors, which helps people fall asleep and stay asleep and can reduce itching.

At higher antidepressant doses it blocks reuptake of serotonin and norepinephrine, providing mood and anxiety benefits but also producing more side effects.

Common side effects vary by dose and include sedation and dry mouth, while higher doses increase risks such as cardiac effects and anticholinergic symptoms.

Scientific Breakdown

Doxepin is classified under ATC code N06AA12 and is a tricyclic antidepressant with dose-dependent pharmacology.

Reuptake Inhibition

At antidepressant-range doses doxepin inhibits the norepinephrine transporter (NET) and the serotonin transporter (SERT), contributing to mood and anxiety effects with typical starting doses around 75 mg/day.

Receptor Blockade

Potent H1 antagonism at very low doses (3–6 mg) explains Silenor’s sleep-maintenance effect with minimal NET/SERT activity at those levels.

Antimuscarinic (M1) and alpha-1 adrenergic blockade occur at higher doses and explain dry mouth, blurred vision, orthostatic hypotension, and urinary retention.

Metabolism Notes

Doxepin is extensively metabolized by the liver, so dose adjustments and careful titration are advised in hepatic impairment and in the elderly.

Available forms include capsules (10–100 mg), oral solution (10 mg/mL), and Silenor tablets (3 and 6 mg) tailored to insomnia versus antidepressant use.

Scope Of Approved And Off-Label Use

United States Approvals

Silenor tablets 3 mg and 6 mg are approved in the United States for insomnia, specifically sleep maintenance.

The Sinequan brand has been discontinued in the U.S., but generic doxepin capsules remain approved and available for depression and related indications.

Regulatory status across other markets includes prescription-only classification and multiple generics in the EU and elsewhere.

Notable Off-Label Trends

Clinicians continue to use doxepin off-label for chronic pruritus in selected patients and for certain neuropathic pain cases where TCA analgesic effects are useful.

Topical past formulations such as Zonalon and Prudoxin were historically used in dermatology for itch management in other markets, though availability is variable.

In psychiatry and primary care SSRIs and SNRIs have largely supplanted doxepin as first-line depression therapy due to tolerability advantages, reserving doxepin for treatment-resistant profiles or when sedative antihistamine properties are preferred.

Approved dosing contrast: for insomnia use Silenor 3–6 mg nightly, while depression dosing typically starts around 75 mg/day and can be titrated to therapeutic ranges under supervision.

Dosage Strategy

General Dosing

Start low and titrate to effect while monitoring anticholinergic and cardiac adverse effects, especially in older adults and those with hepatic impairment.

Abrupt discontinuation should be avoided; tapering gradually reduces risk of withdrawal or discontinuation symptoms.

Condition-Specific Dosing

Depression / Anxiety

Typical adult starting dose for antidepressant effect is 75 mg/day, given at once at bedtime or divided, with a usual therapeutic range of 75–150 mg/day.

Under specialist supervision some patients may require doses up to 300 mg/day with appropriate monitoring for cardiac and anticholinergic effects.

Insomnia (Silenor)

Use Silenor 3–6 mg at bedtime to target H1 receptors for sleep maintenance while minimizing antidepressant-range effects.

Pediatrics / Elderly / Organ Impairment

Doxepin is not recommended for children under 12, and data for those 12 and older are limited, so the lowest effective dose should be used with caution.

Elderly patients are more sensitive to sedation and anticholinergic effects; when treating depression consider starting at lower doses such as 25–50 mg/day and titrating carefully.

Hepatic or severe renal impairment warrants dose reduction and careful clinical monitoring due to altered metabolism and clearance.

When high doses are considered, baseline ECG and regular follow-up are reasonable for patients with cardiac risk factors.

Safety Protocols

Contraindications

Absolute contraindications include known doxepin or tricyclic antidepressant hypersensitivity, narrow-angle glaucoma, urinary retention, and MAOI use within the prior 14 days.

Use in pregnancy and lactation should occur only if clearly needed and after specialist consultation.

Adverse Effects

Common adverse effects include drowsiness, dry mouth, dizziness, blurred vision, constipation, urinary retention, weight gain, and orthostatic hypotension.

Serious adverse events may include cardiac arrhythmias and seizures, which require immediate medical attention.

Risk mitigation begins with pre-treatment screening and continues with appropriate monitoring during therapy.

Pre-Treatment Screening

Assess cardiac history and conduction disorders, hepatic function, prostatic hypertrophy, and suicidality before initiating antidepressant-range doxepin.

Monitoring During Treatment

Consider baseline ECG for patients with cardiovascular disease or when planning high-dose therapy, and reassess within 1–3 weeks for antidepressant response and side effects.

Regularly review anticholinergic burden in elderly patients to reduce risks of cognitive decline and falls.

Overdose Management

Overdose can result in severe drowsiness, confusion, seizures, and cardiac arrhythmias; emergency medical attention is mandatory for suspected overdose.

Missed-dose guidance: take as soon as remembered unless near the next dose and do not double the dose.

Interaction Mapping

Food Interactions

Alcohol potentiates sedation and orthostatic effects, so patients should avoid or limit alcohol while taking doxepin.

Over-the-counter antihistamines and many sleep aids increase anticholinergic burden and additive sedation, especially in older adults.

Drug Combinations To Avoid

MAO inhibitors taken within 14 days are contraindicated because of severe interaction risk.

Concomitant QT‑prolonging drugs and class I/III antiarrhythmics increase arrhythmia risk at antidepressant dosing ranges.

Other strong anticholinergic drugs such as oxybutynin or some antipsychotics have additive side effects and should be used cautiously with doxepin.

Because doxepin is hepatically metabolized, strong CYP inhibitors or inducers can raise or lower doxepin levels; examples include certain antifungals, macrolide antibiotics, and strong CYP2D6 inhibitors like fluoxetine and paroxetine.

Concurrent serotonergic agents may raise the risk of serotonin syndrome; carefully evaluate the combination and monitor patients closely.

Patient Experience Analysis

Survey Data

Patients describe two distinct experiences depending on dose and indication.

Insomnia patients taking Silenor 3–6 mg most commonly report improved sleep maintenance with mild and transient next-day drowsiness.

Patients treated with antidepressant-range doxepin report mood improvements comparable to older TCAs but note higher rates of dry mouth, constipation, orthostatic symptoms, and weight gain compared with SSRIs.

These tolerability differences are a frequent reason clinicians favor SSRIs or SNRIs as first-line agents for depression.

Forum Trends

Online patient forums often praise doxepin for sleep and refractory pruritus, while common complaints include daytime sedation and concerns about cardiac effects at higher doses.

Veterans and older adults sometimes report successful switches from SSRIs to low-dose doxepin when insomnia persists, particularly if sedating properties help both sleep and nighttime anxiety.

Withdrawal stories posted on forums emphasize the importance of gradual tapering to avoid rebound insomnia and discontinuation symptoms.

Patient counseling should note that doxepin is not habit-forming but that abrupt cessation can cause rebound issues, so tapering is recommended.

Distribution & Pricing Landscape

Sinequan branded product is discontinued in the U.S., but generic doxepin capsules (10–100 mg) remain available from manufacturers like Mylan and Teva.

Silenor tablets 3 mg and 6 mg are marketed specifically for insomnia and are generally priced higher than generics due to brand positioning.

Common packaging includes capsules, bottles, blister packs, and pharmacy bulk containers, plus oral solution in some markets for titration needs.

Generic availability has lowered the historical cost for antidepressant-dose doxepin compared with the former Sinequan brand, while Silenor tends to command a premium for insomnia prescriptions.

When sourcing doxepin, confirm authorized suppliers and labeling, especially for topical or less-common formulations which may be subject to import or registration restrictions in some regions.

In our online pharmacy, sinequan is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

The following text-format comparison highlights alternatives and trade-offs.

Doxepin (Low-Dose Silenor 3–6 mg): Pros — effective for sleep maintenance with minimal dependence risk; Cons — limited to insomnia indication at low doses, sedation possible.

Amitriptyline (TCA): Pros — strong antidepressant and analgesic properties; Cons — higher anticholinergic burden and cardiac risk.

Nortriptyline (TCA): Pros — somewhat fewer anticholinergic effects than amitriptyline; Cons — retains TCA-class cardiac and anticholinergic risks.

SSRIs (Sertraline, Fluoxetine): Pros — favorable tolerability and first-line status for depression/anxiety; Cons — sexual dysfunction, potential activation in some patients.

Sedative-Hypnotics (Z-Drugs, Benzodiazepines): Pros — robust hypnotic effects; Cons — dependence risk, rebound insomnia, daytime impairment.

Pros And Cons

Doxepin occupies a niche because its effects are dose-dependent — low doses for H1 blockade and sleep, higher doses for antidepressant effects.

Choose alternatives based on comorbid conditions: TCAs remain valuable for neuropathic pain and certain complex cases, while SSRIs are generally preferred for first-line depression due to tolerability.

Regulatory Status

Doxepin is prescription-only (Rx) across the United States, EU, Australia, Canada, and the UK.

In the United States Sinequan is discontinued, generics are FDA-approved, and Silenor remains approved for insomnia at 3 mg and 6 mg strengths.

European markets have multiple generics with marketing authorizations, and Australia lists Doquel as an equivalent product supplied by Aspen in some channels.

Topical dermatologic products branded historically as Zonalon or Prudoxin have variable registration statuses by country, so check local labeling and registries when prescribing for pruritus.

Pregnancy and lactation counseling should reference specialist guidance and risk–benefit discussion before initiating doxepin therapy.

Consolidated FAQ

Q: Is Sinequan still available?

A: The Sinequan brand is discontinued in the U.S.; generics of doxepin capsules remain available and Silenor is the insomnia-specific brand (3–6 mg).

Q: What dose treats insomnia versus depression?

A: Insomnia — Silenor 3–6 mg at bedtime. Depression/anxiety — typical start is about 75 mg/day with usual ranges of 75–150 mg/day and specialist-managed doses up to 300 mg/day.

Q: Who should avoid doxepin?

A: Avoid in patients with narrow-angle glaucoma, urinary retention, MAOI use within 14 days, and known TCA hypersensitivity; use caution in elderly patients and those with hepatic impairment.

Q: What are common side effects?

A: Drowsiness, dry mouth, dizziness, blurred vision, constipation, urinary retention, weight gain, and orthostatic hypotension; serious risks include arrhythmias and seizures.

Q: How should missed or overdose doses be handled?

A: Missed dose — take when remembered unless close to the next dose and do not double the dose. Overdose — seek immediate medical care for symptoms such as severe drowsiness, seizures, or arrhythmia.

Product reminders: store between 15–30°C and note that doxepin is strictly prescription controlled in major markets except where explicitly provided by a licensed prescriber.

Visual Guide

Designers should create a mechanism infographic showing dose-dependent receptor effects: low-dose H1 blockade for sleep, higher-dose NET/SERT inhibition for antidepressant action, and antimuscarinic/alpha‑1 effects as dose increases.

Include a dosing flowchart beginning with a screening checklist (contraindications and baseline ECG if cardiac risk) then branching to insomnia (Silenor 3–6 mg) or depression (start ~75 mg) with titration and monitoring nodes.

A safety checklist card should call out contraindications, common side effects, overdose red flags, and emergency contacts with clear alt text for accessibility.

Provide packaging and strength mockups showing capsules (10–100 mg), Silenor tablets (3 mg and 6 mg), and oral solution (10 mg/mL) with manufacturer labels such as Mylan, Teva, and Aspen where applicable.

Storage & Transport

Store doxepin at controlled room temperature between 15–30°C (59–86°F) and protect from moisture and excessive heat.

Keep medication in its original packaging during transport to prevent contamination and deterioration and advise patients to return unused medication to a pharmacy for safe disposal when available.

Bulk pharmacy containers should have tamper-evident seals and humidity control in storage areas to protect stability.

Oral solution storage should follow manufacturer labeling; generally room temperature is acceptable unless the label specifies otherwise.

Shipping should avoid prolonged exposure to high temperatures during transit unless the manufacturer specifies cold-chain requirements.

Guidelines For Proper Use

Confirm indication and contraindications before selecting a formulation: use Silenor 3–6 mg nightly for insomnia and doxepin capsules (10–100 mg) for depression with a typical antidepressant start of 75 mg/day.

Conduct baseline assessments including cardiac history, current medications for interactions, hepatic/renal function, and suicidality screening before initiating antidepressant-range therapy.

Schedule a follow-up within 1–3 weeks after initiation or dose change for antidepressant dosing to evaluate response and side effects.

Monitor sleep efficacy and daytime sedation when prescribing Silenor, adjusting dose if morning impairment occurs.

Taper gradually when discontinuing to avoid withdrawal and rebound symptoms rather than stopping abruptly.

Patient counseling points: avoid alcohol, be cautious with OTC antihistamines and anticholinergic products, and report palpitations, syncope, severe confusion, or urinary retention promptly.

In cases of overdose or severe adverse events seek emergency medical attention immediately.

Delivery Across United States

Final Notes For Clinicians And Patients

Dose selection depends on indication: use Silenor for insomnia at 3–6 mg and reserve higher doses for antidepressant effect with careful monitoring.

Be mindful of anticholinergic burden in older adults and of potential drug interactions that affect hepatic metabolism or prolong QT interval.

When counseling patients, explain common side effects and the need to avoid alcohol and additional OTC antihistamines or anticholinergic drugs.

For supply and cost considerations, generic doxepin capsules are widely available and generally less expensive than older branded products, while Silenor often carries premium pricing for insomnia use.

Always verify local prescribing rules and product labeling before dispensing, and encourage patients to contact their pharmacist with questions about dosing, storage, or potential interactions.